<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03342144</url>
  </required_header>
  <id_info>
    <org_study_id>P17-132</org_study_id>
    <nct_id>NCT03342144</nct_id>
  </id_info>
  <brief_title>Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real‑Life Setting</brief_title>
  <official_title>Observational Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An observational study to assess the effectiveness, health economic‐relevant costs and
      patient reported outcomes in patients with Chronic lymphocytic leukemia (CLL) receiving
      venetoclax as prescribed at the discretion of the physician and in accordance with local
      clinical practice and label.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Achieving Overall Response Rate (ORR)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>ORR is defined as the percentage of participants achieving partial response (PR) or complete response (CR) according to physician's assessment to therapy with venetoclax.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) Rate</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Percentage of patients with PFS where PFS is defined as the number of days from the date of entry in the study to the date of the first documented disease progression, start of a subsequent treatment regimen, or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Percentage of patients with OS where OS is defined as the number of days from the date of entry in the study to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30 Scores</measure>
    <time_frame>Up to 104 weeks</time_frame>
    <description>European Organization for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire (QLQ) developed to assess the quality of life of cancer patients. and is based on multi‐item and single‐item scales. The core questionnaire contains 5 functional scales, 3 symptom scales, 1 global health status scale, as well as 6 single‐item measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Complete Response with Incomplete Regeneration of Bone Marrow (CRi)</measure>
    <time_frame>Up 24 months</time_frame>
    <description>Incomplete regeneration of bone marrow (CRi) as defined in the study protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality of Life 5 Dimensions (EQ-5D-5L) including visual analogue scale (VAS)</measure>
    <time_frame>Up 24 months</time_frame>
    <description>The EQ-5D-5L is a standardized non-disease specific instrument for describing and valuing health-related quality of life. EQ‐5D‐5L questionnaire consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ‐5D‐5L questionnaire plus a VAS will be used to assess general health in 5 dimensions (mobility, self‐care, usual activities, pain/discomfort anxiety/depression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-CLL 16/17 Scores</measure>
    <time_frame>Up to 104 weeks</time_frame>
    <description>Quality of Life Questionnaire - Chronic Lymphocytic Leukemia (QLQ-CLL)16/17 is designed for patients with stage 0 to stage 4 chronic lymphocytic leukemia. It is used to assess 5 domains of health-related quality of life important in CLL: fatigue, side effects and symptoms of disease, infection and social activities or future illness‐related concerns.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with Progressive Disease (PD)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Progressive disease as defined in the study protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Partial Response (PR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Partial response as defined in the study protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Administering Venetoclax</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Percentage of patients administering venetoclax throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with Stable Disease (SD)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>SD is defined as percentage of all patients not having PD, but who do not meet the criteria for PR or CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Complete Response (CR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Complete Response as defined in the study protocol.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <arm_group>
    <arm_group_label>Participants Receiving Venetoclax</arm_group_label>
    <description>Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic lymphocytic leukemia (CLL) administering venetoclax per the local
        label.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with chronic lymphocytic leukemia (CLL) administering venetoclax and who meets
             the following conditions as specified in the label for venetoclax:

          -  Venetoclax monotherapy for the treatment of CLL in the presence of deletion chromosome
             17 (del[17p]) or tumor protein p53 (TP53) mutation in adult patients, who are
             unsuitable for or have failed to a B‐cell receptor pathway inhibitor.

          -  Venetoclax monotherapy for the treatment of CLL in the absence of del(17p) or TP53
             mutation in adult patients, who have failed both chemoimmunotherapy and a B‐cell
             receptor pathway inhibitor.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johannes Huelsenbeck</last_name>
    <phone>+49 611-1720-3036</phone>
    <email>johannes.huelsenbeck@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bjoern Tews</last_name>
    <email>bjoern.tews@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Onkologische Praxis</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wurttemberg</state>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum (MVZ)</name>
      <address>
        <city>Aschaffenburg</city>
        <state>Bayern</state>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <state>Bayern</state>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Hornberger &amp; Kollegen</name>
      <address>
        <city>Bad Reichenhall</city>
        <state>Bayern</state>
        <zip>83435</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologie am Segelfliegerdamm</name>
      <address>
        <city>Berlin</city>
        <state>Bayern</state>
        <zip>12487</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologie Hof</name>
      <address>
        <city>Hof</city>
        <state>Bayern</state>
        <zip>95028</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Vehling-Kaiser</name>
      <address>
        <city>Landshut</city>
        <state>Bayern</state>
        <zip>84028</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Grüner/Hejazi/Niewenhuys</name>
      <address>
        <city>Weiden i.d.OPf.</city>
        <state>Bayern</state>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Kreher</name>
      <address>
        <city>Bad Liebenwerda</city>
        <state>Brandenburg</state>
        <zip>04924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MVZ Dres. Cordes &amp; Partner</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>OAZ Hannover</name>
      <address>
        <city>Hanover</city>
        <state>Niedersachsen</state>
        <zip>30171</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkolologische Praxis Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <state>Niedersachsen</state>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MVZ der Paracelsus-Klinik</name>
      <address>
        <city>Osnabrück</city>
        <state>Niedersachsen</state>
        <zip>49076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Med. Studiengesellschaft Nord West GmbH</name>
      <address>
        <city>Westerstede</city>
        <state>Niedersachsen</state>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkozentrum Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BAG Freiberg-Richter</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Berlin</city>
        <zip>10707</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Internistische Schwerpunktprax</name>
      <address>
        <city>Erlangen</city>
        <zip>91052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Luebecker Oncology Practice</name>
      <address>
        <city>Luebeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stauferklinikum Schwaebisch Gm</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia (CLL)</keyword>
  <keyword>Cancer</keyword>
  <keyword>Leukemia</keyword>
  <keyword>venetoclax</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

